Proof-of-Concept Study of EVP-6124, an Alpha-7 Nicotinic Acetylcholine Receptor Agonist, Versus Placebo in Subjects With Nicotine Dependence

Trial Profile

Proof-of-Concept Study of EVP-6124, an Alpha-7 Nicotinic Acetylcholine Receptor Agonist, Versus Placebo in Subjects With Nicotine Dependence

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs Encenicline (Primary) ; Nicotine
  • Indications Smoking withdrawal
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 21 Sep 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 01 Oct 2014 Planned End Date changed from 1 Dec 2014 to 1 Jan 2016 as reported by ClinicalTrials.gov record.
    • 01 Oct 2014 Planned primary completion date changed from 1 Dec 2014 to 1 Jan 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top